palifermin and Daunoxome Interactions

Interactions between palifermin and Daunoxome (DAUNOrubicin liposomal)

DAUNOrubicin liposomal and palifermin (Moderate Drug-Drug)

ADJUST DOSING INTERVAL: In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.

MANAGEMENT: Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.